This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
Key takeaways
- According to an SEC filing dated May 15, 2026, High Vista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter.
- This was a sell; post-trade, the Structure Therapeutics stake represents 1.6491% of HighVista’s reportable U.S. equity AUM
- NYSEMKT:DBC: $30.61 million (8.5% of AUM)
Jonathan Ponciano, The Motley Fool Mon, May 18, 2026 at 1:42 AM GMT+7 4 min read GPCR SYRE ABVX PRAX COGT High Vista Strategies sold 69,092 shares of Structure Therapeutics (NASDAQ:GPCR) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing.
According to an SEC filing dated May 15, 2026, High Vista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter. The estimated transaction value was $4.73 million, calculated using the average closing price for the quarter. The position’s quarter-end value decreased by $7.45 million, a figure that incorporates both the share sale and market price fluctuations.
This was a sell; post-trade, the Structure Therapeutics stake represents 1.6491% of HighVista’s reportable U.S. equity AUM